Hepatitis B virus replication inhibition

“Hepatitis B virus replication inhibition” describes the suppression of hepatitis B virus life cycle processes, particularly targeting the production and amplification of viral DNA within host cells. This goal can be achieved through the inhibition of various viral or host factors, including the HBV polymerase (reverse transcriptase), ribonuclease H (RNaseH), nucleocapsid (capsid) protein, or host antiviral factors like interferon-stimulated genes. Approved antiviral drugs (e.g., nucleoside analogues) work by inhibiting HBV polymerase, and new agents are in development targeting RNase H and capsid assembly, among other functions[2][4][6][7][8]. However, "HBV replication inhibition" itself is not a unique molecule but a collective term for a therapeutic strategy against chronic hepatitis B infection. If you need information about a specific molecular target involved in HBV replication (e.g., "HBV polymerase," "HBV RNaseH," or "HBV core protein"), please specify, and I can return detailed structured data on that molecule.